Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 8/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029916 | 0.89 | BCL9 (0.47) | BCL9CTNNB1PDE4BL3MBTL1 | |
| SCHEMBL4030607 | 0.83 | PDE4B (0.55) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL4030092 | 0.82 | BCL9 (0.58) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL4031722 | 0.82 | BCL9 (0.51) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL6192890 | 0.81 | BCL9 (0.47) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL4031116 | 0.81 | BCL9 (0.57) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL4032590 | 0.81 | BCL9 (0.51) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL4026987 | 0.78 | BCL9 (0.58) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL29087342 | 0.77 | SMN1; SMN2 (0.59) | BCL9CTNNB1PDE4BJAK2JAK1 | |
| SCHEMBL14528931 | 0.75 | ALDH1A1 (0.53) | L3MBTL1HTTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567493-B1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PROD INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | BCL9 2684/4885CTNNB1 2280/4885PDE4B 615/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | BCL9 2684/4885CTNNB1 2280/4885PDE4B 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.